Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

Lung cancers with oncogenic mutations in the epidermal growth factor receptor (EGFR) invariably acquire resistance to tyrosine kinase inhibitor (TKI) treatment. Vulnerabilities of EGFR TKI-resistant cancer cells that could be therapeutically exploited are incompletely understood. Here, we describe a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cell Rep
Главные авторы: Marcar, Lynnette, Bardhan, Kankana, Gheorghiu, Liliana, Dinkelborg, Patrick, Pfäffle, Heike, Liu, Qi, Wang, Meng, Piotrowska, Zofia, Sequist, Lecia V., Borgmann, Kerstin, Settleman, Jeffrey E., Engelman, Jeffrey A., Hata, Aaron N., Willers, Henning
Формат: Artigo
Язык:Inglês
Опубликовано: 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624074/
https://ncbi.nlm.nih.gov/pubmed/31216465
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2019.05.058
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы